

Joana L Mora

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9816187/publications.pdf>

Version: 2024-02-01

12
papers

303
citations

1307594

7
h-index

1474206

9
g-index

14
all docs

14
docs citations

14
times ranked

351
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , 2020, 26, 1280-1284.	30.7	83
2	Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. <i>Neuro-Oncology</i> , 2019, 21, 1401-1411.	1.2	70
3	Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. <i>Nature Communications</i> , 2021, 12, 5954.	12.8	35
4	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. <i>Nature Communications</i> , 2022, 13, 1325.	12.8	31
5	Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid. <i>JAMA Network Open</i> , 2021, 4, e2120040.	5.9	27
6	Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. <i>Nature Communications</i> , 2021, 12, 5955.	12.8	25
7	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2022, 10, 996-1012.	3.4	18
8	Anti-EGFR VHH-armed death receptor ligandâ€“engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers. <i>Science Advances</i> , 2021, 7, .	10.3	10
9	IMMU-02. GENOMIC AND TRANSCRIPTOMIC CORRELATES OF IMMUNOTHERAPY RESPONSE WITHIN THE TUMOR MICROENVIRONMENT OF LEPTOMENINGEAL METASTASES. <i>Neuro-Oncology</i> , 2021, 23, vi92-vi92.	1.2	0
10	CTIM-30. PHASE II TRIAL OF PEMBROLIZUMAB IN RECURRENT AND RESIDUAL HIGH-GRADE MENINGIOMAS. <i>Neuro-Oncology</i> , 2021, 23, vi57-vi57.	1.2	0
11	BIOM-04. SENSITIVE DETECTION OF LEPTOMENINGEAL DISEASE USING CELL-FREE DNA FROM CEREBROSPINAL FLUID. <i>Neuro-Oncology</i> , 2021, 23, vi10-vi10.	1.2	0
12	CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. <i>Neuro-Oncology</i> , 2021, 23, vi49-vi49.	1.2	0